Pharmacy - Emergency Medicine Deep Dive Podcast

Episodet

• Prolonged Beta-Lactam Infusion Strategies in Sepsis: A Deeper Dive 26.06.2026 24min

  Sepsis demands timely, effective antimicrobial therapy, but does how we administer beta-lactam antibiotics matter? In this episode, we take a deeper dive into the growing evidence behind prolonged beta-lactam infusion strategies and explore why recent guidelines now recommend extended or continuous infusions for many patients with sepsis and septic shock. We unpack the pharmacokinetic and pharmacodynamic principles, review key clinical trials and meta-analyses demonstrating improved outcomes, and discuss the critical role of an appropriate loading dose. We also examine which patient populations may benefit the most, including those with augmented renal clearance or altered physiology and when therapeutic drug monitoring should be considered. Finally, we tackle the practical challenges of implementing prolonged infusions in clinical practice, from drug stability and IV compatibility to the unanswered questions surrounding antimicrobial resistance.
• Ketamine During OAT Initiation: Can It Help in the Fentanyl Era? 15.06.2026 19min

  Ketamine is best known for its roles in analgesia, sedation, and depression, but could it also help patients navigate the most challenging phase of opioid agonist therapy initiation in the fentanyl era? In this episode, we explore the emerging science behind ketamine as an adjunctive treatment for opioid withdrawal and OAT initiation, including its potential effects on NMDA receptors, opioid tolerance, and receptor signaling. We review the latest clinical evidence, from case reports of refractory withdrawal to early studies suggesting improved retention in treatment through rapid relief of depression and withdrawal distress. We'll also unpack the fascinating biology of beta-arrestin, receptor internalization, and whether ketamine may help improve opioid responsiveness by rebalancing some of the neurobiological changes associated with chronic fentanyl exposure. Join us as we separate promise from proof and discuss where ketamine may fit and where it may not in the future of addiction care.
• Time Is Blood: Why Early TXA Saves Lives in Trauma 14.06.2026 21min

  In this episode, we explore the race against time in trauma care and why every minute matters when treating life-threatening bleeding. Drawing on evidence from major clinical trials and meta-analyses, we examine how tranexamic acid (TXA) can dramatically improve survival when administered as early as possible after injury. You'll learn why the greatest benefits occur within the first hour, why effectiveness begins to decline after 90 minutes, and how even short delays can significantly reduce a patient's chance of survival. We also discuss emerging evidence suggesting that rapid treatment may be more important than where the treatment is delivered. Whether you're a healthcare professional, student, or simply interested in emergency medicine, this episode highlights how timely intervention can save lives in trauma, hemorrhagic shock, and traumatic brain injury.
• Blood Pressure Management in Acute Intracerebral Hemorrhage 02.06.2026 22min

  How low should you go when lowering blood pressure in acute intracerebral hemorrhage, and can treating too aggressively actually cause harm? In this episode, we explore the pathophysiology of ICH, including why spontaneous hemorrhage lacks a true ischemic penumbra and how perihematomal benign oligemia supports the safety of blood pressure reduction. We review the landmark INTERACT-2 and ATACH-II trials, along with the newer INTERACT-3 and INTERACT-4 studies, to uncover how the evidence has shaped modern practice and reinforced the lesson that lower is not always better. We discuss current guideline recommendations, including the shift toward a systolic blood pressure target of 130 to 150 mmHg and the importance of minimizing blood pressure variability. Finally, we compare commonly used agents such as nicardipine and clevidipine and revisit the longstanding controversy surrounding hydralazine and its purported effects on intracranial pressure and hematoma expansion.
• Clinical Management of Toxicological Seizures 19.05.2026 21min

  In toxicology-induced status epilepticus, the clock starts ticking the moment first-line benzodiazepines fail. In this episode, we dive into the evolving evidence behind second-line therapies for benzodiazepine-refractory seizures, exploring why phenobarbital remains the best-supported option based on pharmacologic principles and animal data, while propofol emerges as a powerful rescue therapy in intubated patients. We also unpack the growing interest in levetiracetam, a medication praised for its favorable safety profile and minimal cardiorespiratory effects, but whose effectiveness in toxicologic seizures remains uncertain, particularly in stimulant-related cases highlighted by the ESETT subgroup analysis. Along the way, we examine why older agents like phenytoin may have little to no role in poisoned patients despite their historic use in seizure management. Through real-world clinical dilemmas, pharmacology insights, and emerging research, we explore how emergency clinicians navigate the race to stop seizures before irreversible neurological injury occurs. Whether you’re passionate about emergency medicine, toxicology, critical care, or neuropharmacology, this episode delivers a fascinating look at one of medicine’s highest-stakes treatment decisions.
• Tenecteplase vs Alteplase: The Evolving Standard for Ischemic Stroke 12.05.2026 23min

  Stroke thrombolysis is rapidly evolving and tenecteplase is emerging as one of the most exciting developments in acute ischemic stroke care. In this episode, we explore how a simple change from a one-hour infusion to a single IV bolus could transform stroke treatment workflows, improve transfer logistics, and potentially enhance early reperfusion in some patients. We unpack the science behind tenecteplase, review the landmark trials that challenged alteplase’s decades-long dominance, and discuss why clinicians around the world are paying close attention. From breakthrough studies in large vessel occlusion to major safety and non-inferiority trials, this episode highlights the evidence shaping modern stroke practice. This episode offers a practical and engaging overview of one of the biggest shifts in contemporary stroke care.
• Pharmacological Priorities in Emergency Upper Gastrointestinal Bleeding 06.05.2026 50min

  In this episode, we dive into the evolving evidence behind proton pump inhibitors (PPIs) in the management of nonvariceal upper gastrointestinal bleeding. While PPIs have long been considered standard early therapy, emerging data challenge whether starting treatment before endoscopy meaningfully improves major clinical outcomes such as mortality, surgery, or overall rebleeding rates. We explore how current evidence suggests the clearest benefit may be in patients with confirmed peptic ulcer bleeding, where PPIs can help reduce recurrent bleeding after endoscopic therapy. The episode also examines the growing shift away from continuous IV infusions toward intermittent dosing strategies, which appear similarly effective while potentially reducing cost and resource use. Join us as we unpack how evidence-based medicine is reshaping long-standing practices in emergency gastrointestinal care.
• Is Ondansetron Really Dangerous? A Deep Dive into the Data 27.04.2026 17min

  Ondansetron is a widely used antiemetic, but concerns have long circulated about its potential to prolong the QT interval and trigger dangerous arrhythmias like torsades de pointes. In this episode, we explore what the evidence actually shows, drawing on large-scale research including a review of over 32,000 surgical patients and a meta-analysis of 170 clinical trials. The data consistently suggests that at standard low doses, the risk of serious cardiac events is extremely low for most patients. We also unpack why reported adverse outcomes are often linked to underlying heart conditions rather than the medication itself, and how administration strategies like slower IV delivery or oral dosing may further reduce risk. Finally, we examine whether routine ECG monitoring is truly necessary in low-risk patients and what this means for everyday clinical practice.
• Safety of Co-administering Olanzapine and Benzodiazepines for Acute Agitation 23.04.2026 21min

  In this episode, we unpack the long-standing controversy around combining IM olanzapine with benzodiazepines like lorazepam in the management of acute agitation. While warnings from regulators such as the U.S. Food and Drug Administration have historically discouraged this pairing due to concerns about respiratory depression, we take a closer look at the data behind those risks. Emerging evidence suggests that adverse outcomes may be less common than previously feared, especially when doses are spaced appropriately and polypharmacy is minimized. We explore how this evolving literature challenges rigid institutional practices and what it means for bedside decision making in the ED. Tune in for a practical, evidence based approach to balancing safety and effectiveness in agitation management.
• Corticosteroids in Severe Pneumonia: The CAPE COD Debate 17.04.2026 20min

  In this episode, we break down the landmark CAPE COD trial and what it means for treating severe community-acquired pneumonia. Discover how early hydrocortisone use can significantly reduce mortality and the need for mechanical ventilation in critically ill patients, and why that is reshaping clinical practice. We also explore contrasting evidence from other studies, fueling an ongoing debate about when steroids truly make a difference. From patient selection to risks like hyperglycemia, we unpack the nuance behind the headlines. Tune in to understand where the evidence stands and how it is changing the way clinicians approach severe pneumonia.
• Hypertonic Saline and Furosemide in Acute Heart Failure Management 06.04.2026 22min

  What if a simple shift in how we use fluids and diuretics could transform outcomes in acute heart failure? In this episode, we explore the emerging strategy of combining hypertonic saline with high dose furosemide and why it is gaining attention in acute decompensated heart failure care. We break down how this approach can enhance fluid removal, improve kidney function, and even reduce mortality and hospital length of stay. You will also learn why this therapy may be especially valuable for patients with diuretic resistance, kidney dysfunction, or low sodium levels. We unpack the physiology behind improved renal blood flow and reduced harmful hormonal activation, while addressing common safety concerns. Finally, we examine the limitations of current evidence and what still needs to be answered before this strategy becomes mainstream.
• CCM 2026 Surviving Sepsis Campaign Guidelines: Precision Pharmacotherapy Unpacked 30.03.2026 32min

  Sepsis care is entering a new era, as the 2026 CCM Surviving Sepsis Guidelines shift practice away from “throw everything at it” toward precision pharmacotherapy, giving the right drugs at the right dose and stopping unnecessary ones early. In this episode, we break down the strongest recommendations, from extended-infusion β-lactams that optimize antibiotic exposure to permissive hypotension strategies in older adults that reduce vasopressor use. We also explore the end of the “vitamin era,” with IV Vitamin C and D no longer recommended, and where corticosteroids still play a conditional role in septic shock. Fluid therapy guidance now favors balanced crystalloids to protect kidney function, while aggressive antimicrobial stewardship emphasizes de-escalation and avoiding routine empiric coverage. Tune in to understand how these landmark updates are reshaping critical care practice and making sepsis treatment smarter, safer, and more precise.
• Essential Clinical Pearls for DOAC Therapy 23.03.2026 11min

  Choosing the right DOAC is not just about preventing clots, it is about maximizing safety for every patient. In this episode, we unpack the latest evidence on direct oral anticoagulants, including the practice changing COBRRA trial comparing apixaban and rivaroxaban. Discover why similar effectiveness can come with very different bleeding risks, and how that should shape your prescribing decisions. We also explore high yield clinical pearls, from taking rivaroxaban with food to renal dosing and the unique properties of each DOAC. Whether you are in practice or still learning, this episode will help you confidently navigate DOAC selection in real world care.
• Critical Care Antibiotic Pharmacokinetics and Dosing Strategies 16.03.2026 21min

  What happens to antibiotics when the body is in crisis? In this episode, we dive into the fascinating and often unpredictable pharmacokinetic changes that occur in critically ill patients and why these shifts make precise antibiotic dosing essential. We explore how conditions such as sepsis and aggressive fluid resuscitation can dramatically alter drug distribution and clearance, especially for hydrophilic medications compared with their lipophilic counterparts. Along the way, we unpack key concepts like half life, steady state, and the role of loading doses in reaching therapeutic targets quickly. We also break down the difference between time dependent and concentration dependent antibiotic strategies and how these principles guide real world dosing decisions. Join us as we translate complex pharmacology into practical insights for navigating the high stakes environment of critical care medicine.
• Ketamine for Rapid Control of Excited Delirium 09.03.2026 23min

  When a patient arrives in the emergency department in a state of extreme agitation or excited delirium, every second counts. In this episode, we explore the growing use of ketamine as a rapid intervention to control dangerous psychomotor agitation when traditional sedatives may act too slowly. Research shows ketamine can achieve adequate sedation far faster than medications like haloperidol, lorazepam, or midazolam, helping protect both patients and medical teams in high risk situations. But speed comes with tradeoffs, including a higher risk of complications such as hypoxia and the possible need for airway support. We unpack what the literature says about when ketamine may be appropriate and why careful cardiopulmonary monitoring is essential. Join us as we examine how clinicians balance urgency, safety, and evidence when managing one of the most challenging emergencies in acute care.
• ACLS Medications 2025: What the AHA Guidelines Really Say 02.03.2026 17min

  In this episode, we unpack the 2025 ACLS medication updates from the American Heart Association and what they mean for real-world cardiac arrest care. Epinephrine remains the standard for improving short-term survival, but evidence is still limited when it comes to long-term neurological outcomes. Alternative vasopressors and high-dose strategies show no clear advantage and routine use of calcium, sodium bicarbonate, and magnesium is not recommended. We also explore the nuanced role of amiodarone and lidocaine in select shockable arrests. Above all, the guidelines reinforce what saves lives most: rapid defibrillation, high-quality CPR, and getting the basics right.
• Still Febrile: When Ongoing Fevers Don’t Mean Treatment Failure 06.02.2026 14min

  The fever persists but does that mean treatment is failing? Not necessarily. In this episode we unpack why ongoing fevers do not automatically signal the need to escalate antibiotics. Instead, smart stewardship focuses on the bigger picture including hemodynamic stability, improving organ function, and microbiologic data that reveal the true course of infection. You will learn how to interpret persistent fevers, avoid unnecessary drug toxicity, and make informed decisions that fight antibiotic resistance all without overreacting to the thermometer.
• When Medications Fail: Can Keto Stop Seizures? 25.01.2026 12min

  Drug resistant status epilepticus and seizures are some of the highest stakes emergencies in the ED. In this episode, we explore the ketogenic diet as an emerging strategy for patients who continue seizing despite standard therapy. We highlight how quickly seizure control can be achieved, why early initiation in critically ill patients is gaining attention, and how this therapy is starting to influence acute care decision making. Tune in to see how a traditionally outpatient therapy is stepping into the ED and ICU playbook for bedside seizure management.
• Ketamine and Second-Line Agents in Status Epilepticus Management 25.01.2026 15min

  Status epilepticus is a true neurologic emergency where every minute matters. In this episode, we review modern emergency management strategies, starting with benzodiazepines as first line therapy and examining why traditional second line agents like levetiracetam often fall short in rapidly stopping seizures. We explore growing evidence supporting the early use of ketamine, highlighting its ability to terminate refractory seizures while maintaining hemodynamic stability and often avoiding immediate intubation. The discussion emphasizes the importance of adequate early dosing and decisive escalation to prevent long term neurologic injury. Ultimately, this episode makes the case for faster, more aggressive intervention to achieve seizure control within the critical first thirty minutes.
• From Rate to Rhythm: Why Early Treatment Changes Atrial Fibrillation Outcomes 19.01.2026 12min

  Rate control has long been the default strategy for atrial fibrillation, reserving rhythm control primarily for symptom management. In this episode, we examine the EAST-AFNET 4 trial and the evidence supporting early rhythm control as a means to reduce stroke and cardiovascular death in patients diagnosed within the past year. We discuss how timely initiation of anti arrhythmic therapy or catheter ablation differs fundamentally from delayed rhythm strategies studied in earlier trials. The episode explores why these findings challenge longstanding practice patterns and how they may redefine standard care for newly diagnosed atrial fibrillation, even in minimally symptomatic patients.